Skip to main content
. 2019 Dec 20;14(12):e0226853. doi: 10.1371/journal.pone.0226853

Fig 7. Apportionment of the 59 NSCLC patients with at least one variant identified in liquid biopsy analysis, using 4 different biomarker categories: traditional targeted treatment biomarkers (EGFR, ALK); all approved treatment associated biomarkers (EGFR, ALK, BRAF); approved and emerging treatment biomarkers (EGFR, ALK, BRAF, HER2); approved, emerging treatment & clinical trials associated biomarkers (EGFR, ALK, BRAF, HER2, KRAS, NRAS, MET, PIK3CA, STK11,TP53).

Fig 7

In case a patient harbors more than one mutation the categorization is based on the more clinically significant variant.